Abstract:

Since there is no abstract, we provide the first paragraph

 

Antiangiogenic therapy for cancer represents a major hope of current research. Given the dependence of tumor growth and metastasis on blood vessels, agents that block the development on new blood vessels (neo-angiogenesis) might be effective in improving outcome of cancer patients. Nevertheless, nearly three decades after the first publication of the concept that angiogenesis is a rational target for therapy and successful preclinical research [1], there are still challenges in integrating anti-angiogenesis therapy into clinical practice [2, 3].